CN107041139A - 海兔脯氨酸‑海兔异亮氨酸肽的衍生物 - Google Patents

海兔脯氨酸‑海兔异亮氨酸肽的衍生物 Download PDF

Info

Publication number
CN107041139A
CN107041139A CN201580041582.0A CN201580041582A CN107041139A CN 107041139 A CN107041139 A CN 107041139A CN 201580041582 A CN201580041582 A CN 201580041582A CN 107041139 A CN107041139 A CN 107041139A
Authority
CN
China
Prior art keywords
methyl
amino
pyrrolidin
mmol
base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580041582.0A
Other languages
English (en)
Chinese (zh)
Inventor
B·A·门德尔松
J·度戈尔-特里尔
S·D·巴恩彻
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agensys Inc
Original Assignee
Agensys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agensys Inc filed Critical Agensys Inc
Publication of CN107041139A publication Critical patent/CN107041139A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201580041582.0A 2014-05-28 2015-05-27 海兔脯氨酸‑海兔异亮氨酸肽的衍生物 Pending CN107041139A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462004084P 2014-05-28 2014-05-28
US62/004,084 2014-05-28
PCT/US2015/032704 WO2015183978A1 (en) 2014-05-28 2015-05-27 Derivatives of dolaproine-dolaisoleuine peptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202610089819.2A Division CN121949442A (zh) 2014-05-28 2015-05-27 海兔脯氨酸-海兔异亮氨酸肽的衍生物

Publications (1)

Publication Number Publication Date
CN107041139A true CN107041139A (zh) 2017-08-11

Family

ID=54699722

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580041582.0A Pending CN107041139A (zh) 2014-05-28 2015-05-27 海兔脯氨酸‑海兔异亮氨酸肽的衍生物

Country Status (9)

Country Link
US (2) US20170190735A1 (https=)
EP (1) EP3149024B9 (https=)
JP (3) JP2017519740A (https=)
KR (1) KR102413079B1 (https=)
CN (1) CN107041139A (https=)
ES (1) ES2883023T3 (https=)
RU (1) RU2747989C2 (https=)
SG (1) SG11201609739UA (https=)
WO (1) WO2015183978A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024230625A1 (zh) * 2023-05-06 2024-11-14 荣昌生物制药(烟台)股份有限公司 一种奥瑞他汀衍生物中间体的制备方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3149024B9 (en) * 2014-05-28 2021-10-27 Agensys, Inc. Cytotoxic dolaproine-dolaisoleuine peptide derivatives for the treatment of cancer
WO2017058808A1 (en) * 2015-10-02 2017-04-06 Sirenas Llc Anti-cancer compounds and conjugates thereof
EP4321522A1 (en) * 2022-08-12 2024-02-14 Seagen Inc. Cytotoxic compounds and conjugates thereof

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06234790A (ja) * 1993-02-09 1994-08-23 Teikoku Hormone Mfg Co Ltd 新規テトラペプチドアミド誘導体
EP0695757A2 (en) * 1994-08-01 1996-02-07 Arizona Board Of Regents Human cancer inhibitory peptide amides
EP0695758A2 (en) * 1994-08-01 1996-02-07 Arizona Board Of Regents Human cancer inhibitory pentapeptide amides and esters
US5654399A (en) * 1991-08-09 1997-08-05 Teikoku Hormone Mfg. Co., Ltd. Tetrapeptide derivative having antitumor activity
WO2001018032A2 (en) * 1999-09-10 2001-03-15 Basf Aktiengesellschaft Dolastatin peptides
WO2002088172A2 (en) * 2001-04-30 2002-11-07 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
WO2007008603A1 (en) * 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus
CN101242816A (zh) * 2005-06-30 2008-08-13 维罗贝股份有限公司 Hcv抑制剂
WO2013072813A2 (en) * 2011-11-17 2013-05-23 Pfizer Inc. Cytotoxic peptides and antibody drug conjugates thereof
US20130190248A1 (en) * 2011-07-26 2013-07-25 Agensys, Inc. Substituted peptide analogs
WO2013173391A1 (en) * 2012-05-15 2013-11-21 Concortis Biosystems, Corp Drug-conjugates, conjugation methods, and uses thereof
US20140050746A1 (en) * 2008-03-18 2014-02-20 Seattle Genetics, Inc. Auristatin drug linker conjugates
WO2014072897A1 (en) * 2012-11-07 2014-05-15 Pfizer Inc. Anti-notch3 antibodies and antibody-drug conjugates
WO2014072888A1 (en) * 2012-11-07 2014-05-15 Pfizer Inc. Anti-il-13 receptor alpha 2 antibodies and antibody-drug conjugates

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569834B1 (en) 1992-12-03 2003-05-27 George R. Pettit Elucidation and synthesis of antineoplastic tetrapeptide w-aminoalkyl-amides
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
KR100332254B1 (ko) * 1993-10-01 2002-09-27 데이꼬꾸 조끼 세이야꾸 가부시키가이샤 신규인펩티드유도체
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
ATE459364T1 (de) 2003-10-22 2010-03-15 Univ Johns Hopkins Verbesserte bakteriolyse-kombinationstherapie für die behandlung von tumoren
KR20070050918A (ko) * 2004-07-02 2007-05-16 뉴텍 파마 피엘씨 암의 치료
WO2006132670A2 (en) 2004-11-12 2006-12-14 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the n terminus
US7608592B2 (en) 2005-06-30 2009-10-27 Virobay, Inc. HCV inhibitors
CN106986926A (zh) 2008-01-30 2017-07-28 皮里斯股份公司 具有对人c‑met受体酪氨酸激酶的亲和性的泪脂质运载蛋白的突变蛋白及其获得方法
EP2276509B1 (en) 2008-04-11 2016-06-15 Seattle Genetics, Inc. Detection and tratment of pancreatic, ovarian and other cancers
KR102023496B1 (ko) 2011-04-21 2019-09-20 시애틀 지네틱스, 인크. 신규 결합제-약물 콘주게이트 (adc) 및 그의 용도
RU2566693C2 (ru) * 2011-07-08 2015-10-27 Сименс Акциенгезелльшафт Система слоев с двухслойным металлическим слоем
EP3149024B9 (en) * 2014-05-28 2021-10-27 Agensys, Inc. Cytotoxic dolaproine-dolaisoleuine peptide derivatives for the treatment of cancer

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654399A (en) * 1991-08-09 1997-08-05 Teikoku Hormone Mfg. Co., Ltd. Tetrapeptide derivative having antitumor activity
JPH06234790A (ja) * 1993-02-09 1994-08-23 Teikoku Hormone Mfg Co Ltd 新規テトラペプチドアミド誘導体
EP0695757A2 (en) * 1994-08-01 1996-02-07 Arizona Board Of Regents Human cancer inhibitory peptide amides
EP0695758A2 (en) * 1994-08-01 1996-02-07 Arizona Board Of Regents Human cancer inhibitory pentapeptide amides and esters
WO2001018032A2 (en) * 1999-09-10 2001-03-15 Basf Aktiengesellschaft Dolastatin peptides
WO2002088172A2 (en) * 2001-04-30 2002-11-07 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
CN101242816A (zh) * 2005-06-30 2008-08-13 维罗贝股份有限公司 Hcv抑制剂
WO2007008603A1 (en) * 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus
US20140050746A1 (en) * 2008-03-18 2014-02-20 Seattle Genetics, Inc. Auristatin drug linker conjugates
US20130190248A1 (en) * 2011-07-26 2013-07-25 Agensys, Inc. Substituted peptide analogs
WO2013072813A2 (en) * 2011-11-17 2013-05-23 Pfizer Inc. Cytotoxic peptides and antibody drug conjugates thereof
WO2013173391A1 (en) * 2012-05-15 2013-11-21 Concortis Biosystems, Corp Drug-conjugates, conjugation methods, and uses thereof
WO2014072897A1 (en) * 2012-11-07 2014-05-15 Pfizer Inc. Anti-notch3 antibodies and antibody-drug conjugates
WO2014072888A1 (en) * 2012-11-07 2014-05-15 Pfizer Inc. Anti-il-13 receptor alpha 2 antibodies and antibody-drug conjugates

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GEORGE R.PETTIT ET AL.: "Antineoplastic agents 365. Dolastatin 10 SAR probes", 《ANTI-CANCER DRUG DESIGN》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024230625A1 (zh) * 2023-05-06 2024-11-14 荣昌生物制药(烟台)股份有限公司 一种奥瑞他汀衍生物中间体的制备方法
TWI889323B (zh) * 2023-05-06 2025-07-01 大陸商榮昌生物製藥（煙臺）股份有限公司 一種奧瑞他汀衍生物中間體的製備方法

Also Published As

Publication number Publication date
JP2017519740A (ja) 2017-07-20
KR102413079B1 (ko) 2022-06-24
RU2747989C2 (ru) 2021-05-18
WO2015183978A1 (en) 2015-12-03
EP3149024A1 (en) 2017-04-05
JP7292366B2 (ja) 2023-06-16
JP2022027896A (ja) 2022-02-14
US20220204557A1 (en) 2022-06-30
EP3149024B9 (en) 2021-10-27
US20200325170A1 (en) 2020-10-15
JP2020128405A (ja) 2020-08-27
RU2016150426A3 (https=) 2018-12-20
JP6995160B2 (ja) 2022-01-14
US20170190735A1 (en) 2017-07-06
US11312748B2 (en) 2022-04-26
KR20170005495A (ko) 2017-01-13
ES2883023T3 (es) 2021-12-03
RU2016150426A (ru) 2018-07-03
EP3149024A4 (en) 2018-06-06
EP3149024B1 (en) 2021-05-12
SG11201609739UA (en) 2016-12-29

Similar Documents

Publication Publication Date Title
JP7292366B2 (ja) ドラプロイン‐ドライソロイインペプチド誘導体
TWI248444B (en) FAP-activated anti-tumour compounds
TW202309063A (zh) 具有相對於ｈｒａｓ與ｎｒａｓ選擇性ｋｒａｓ抑制作用的環狀化合物
US11229711B2 (en) Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use
TW202309064A (zh) 環狀胜肽化合物的醫藥用途
TW202434275A (zh) 含有相對於ｈｒａｓ與ｎｒａｓ具有選擇性ｋｒａｓ抑制作用之環狀化合物的醫藥組成物
CN113861268A (zh) 细胞穿透肽及其制备和使用方法
BRPI0213223B1 (pt) Polipeptídeo, dímero ou multímero, polinucleotídeo, vetor de expressão, célula hospedeira, composição farmacêutica, e, uso de uma composição
MX2011004019A (es) Conjugados de etoposido y doxorubicina para entrega de farmacos.
US11046739B2 (en) BH4 stabilized peptides and uses thereof
TW202116356A (zh) 作為治療劑之微管靶向藥劑之肽結合物
KR102436012B1 (ko) 항암제 프로드러그 컨쥬게이트의 새로운 용도
CN116917278A (zh) 用于靶向递送应用的二价成纤维细胞活化蛋白配体
JP7440914B2 (ja) ホウ素中性子捕捉療法用の腫瘍組織を短時間で選択的ないし局所的に標的化できる集積性ボロン１０薬剤
CN111511917B (zh) 肽结合物
CN114409562B (zh) 一种ca4衍生物及其配体-药物偶联物
PL184147B1 (pl) Antagoniści bicyklicznych tachokinin i farmaceutyczna kompozycja zawierająca te związki
HK1243085A1 (en) Derivatives of dolaproine-dolaisoleuine peptides
US20200347136A1 (en) Constrained cyclic peptides as inhibitors of the cd2:cd58 protein-protein interaction for treatment of diseases and autoimmune disorders
WO2024067477A1 (zh) 抗cd33抗体和抗cd33抗体-药物偶联物及其用途
HK40109540A (zh) 反式环辛烯缀合物
TW202417465A (zh) 環肽或其鹽及ｍｄｍｘ抑制劑
CN121949442A (zh) 海兔脯氨酸-海兔异亮氨酸肽的衍生物
HK40094591A (zh) 抗人trop2抗体-喜树碱类药物偶联物及其医药用途
CN115605495A (zh) 用于预防或治疗癌症的药物组合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1243085

Country of ref document: HK

CB03 Change of inventor or designer information
CB03 Change of inventor or designer information

Inventor after: B A Mendelsohn

Inventor after: J. Dugal taisier

Inventor after: S.D. Barncher

Inventor before: B A Mendelsohn

Inventor before: J - Gore - Trier

Inventor before: S.D. Barncher